CURRENT REPORT 06/2022

May 12th, 2022

New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Hybrid Congress 2022

The Management Board of Ryvu Therapeutics S.A. with its registered office in Kraków ("Company") hereby announces that three abstracts demonstrating data from the Phase 1b dose-escalation study of RVU120 (SEL120) in patients with AML or high-risk myelodysplastic syndromes (HR-MDS) and the Phase 1/2 study of SEL24(MEN1703) in Patients with IDH1/2-Mutated AML will be presented at the Annual European Hematology Association (EHA) 2022 Hybrid Congress, June 9-17 2022 in Vienna, Austria and on-line.

Details of poster presentations are as follows:

RVU120: orally available CDK8/19 inhibitor

- **Abstract Title**: *Preclinical and Clinical Signs of RVU120 Efficacy, a Specific CDK8/19 Inhibitor in DNMT3A Mutation Positive AML and HR-MDS*
  Abstract number: #P450
  Session date and time: Friday, June 10, 2022, 16:30 – 17:45 CEST

Preclinical data demonstrates differential sensitivity to RVU120 treatment in DNMT3 and NPM1 mutated AML Patient-Derived Cells (PDCs) *in vitro* and *in vivo*. Anti-cancer efficacy of RVU120 was associated with transcriptomic reprogramming involving inhibition of homeobox genes and induction of lineage commitment markers. Preliminary evidence of clinical response to RVU120 has also been shown in relapsed/refractory (R/R) AML and HR-MDS patients positive for DNMT3A and NPM1 mutations. Both mutations cooperate and define molecular subset of AML, characterized by elevated expression of homeobox genes. Further molecular studies confirming molecular mechanism of action and potential stratification markers are ongoing in more patients treated with RVU120.

- **Abstract Title***: CLI120-001 Phase1b Dose Escalation Study of RVU120 in Patients with AML or High-Risk MDS Safety and Efficacy Data Update*
  Abstract Number*:* #P501
  Session date and time: Friday, June 10, 2022, 16:30 – 17:45 CEST

The presentation includes preliminary results from the first six patient cohorts, which demonstrated a favourable safety and a predictable pharmacokinetic (PK) profile of RVU120. Meaningful pharmacodynamic (PD) activity and clinical efficacy have been observed at the 50 and 75 mg doses.

Enrollment in the trial continues with highest dose cohort now receiving 85 mg of RVU120 (NCT04021368).

SEL24 (MEN1703): orally available dual PIM/FLT3 inhibitor

- **Abstract Title***: Phase 1/2 Study of SEL24/MEN1703, a First-In-Class Dual PIM/FLT3 Kinase Inhibitor, in Patients with IDH1/2-Mutated Acute Myeloid Leukemia: The DIAMOND-01 Trial*
  Abstract Number*:* #P520
  Session date and time: Friday, June 10, 2022, 16:30 – 17:45 CEST

Ryvu's partner Menarini Group reports the updated safety and efficacy results from an additional expansion cohort of the DIAMOND-01 trial which enrolled patients with relapsed or refractory (R/R) IDHm AML treated with the dual PIM/FLT3 inhibitor SEL24 (MEN1703). SEL24/MEN1703 demonstrated a manageable safety profile and single-agent activity in patients with R/R IDHm AML.

The full texts of abstracts are available at: https://ehaweb.org/

The EHA conference is considered one of the most important scientific events, gathering researchers, as well as potential clients and business partners - biotechnology and pharmaceutical companies and industry investors.

Legal basis: Article 17.1 of MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Krzysztof Brzózka – Vice President of the Management Board